In order to develop more precise and functional affective applications, it is necessary to achieve a balance between the psychology and the engineering applied to emotions. Signals from the central and peripheral nervous systems have been used for emotion recognition purposes, however, their operation and the relationship between them remains unknown. In this context, in the present work, we have tried to approach the study of the psychobiology of both systems in order to generate a computational model for the recognition of emotions in the dimension of valence. To this end, the electroencephalography (EEG) signal, electrocardiography (ECG) signal and skin temperature of 24 subjects have been studied. Each methodology has been evaluated individually, finding characteristic patterns of positive and negative emotions in each of them. After feature selection of each methodology, the results of the classification showed that, although the classification of emotions is possible at both central and peripheral levels, the multimodal approach did not improve the results obtained through the EEG alone. In addition, differences have been observed between cerebral and peripheral responses in the processing of emotions by separating the sample by sex; though, the differences between men and women were only notable at the peripheral nervous system level.

Background: More sensitive and less burdensome efficacy end points are urgently needed to improve the effectiveness of clinical drug development for Alzheimer disease (AD). Although conventional end points lack sensitivity, digital technologies hold promise for amplifying the detection of treatment signals and capturing cognitive anomalies at earlier disease stages. Using digital technologies and combining several test modalities allow for the collection of richer information about cognitive and functional status, which is not ascertainable via conventional paper-and-pencil tests. Objective: This study aimed to assess the psychometric properties, operational feasibility, and patient acceptance of 10 promising technologies that are to be used as efficacy end points to measure cognition in future clinical drug trials. Methods: The Method for Evaluating Digital Endpoints in Alzheimer Disease study is an exploratory, cross-sectional, noninterventional study that will evaluate 10 digital technologies’ ability to accurately classify participants into 4 cohorts according to the severity of cognitive impairment and dementia. Moreover, this study will assess the psychometric properties of each of the tested digital technologies, including the acceptable range to assess ceiling and floor effects, concurrent validity to correlate digital outcome measures to traditional paper-and-pencil tests in AD, reliability to compare test and retest, and responsiveness to evaluate the sensitivity to change in a mild cognitive challenge model. This study included 50 eligible male and female participants (aged between 60 and 80 years), of whom 13 (26%) were amyloid-negative, cognitively healthy participants (controls); 12 (24%) were amyloid-positive, cognitively healthy participants (presymptomatic); 13 (26%) had mild cognitive impairment (predementia); and 12 (24%) had mild AD (mild dementia). This study involved 4 in-clinic visits. During the initial visit, all participants completed all conventional paper-and-pencil assessments. During the following 3 visits, the participants underwent a series of novel digital assessments. Results: Participant recruitment and data collection began in June 2020 and continued until June 2021. Hence, the data collection occurred during the COVID-19 pandemic (SARS-CoV-2 virus pandemic). Data were successfully collected from all digital technologies to evaluate statistical and operational performance and patient acceptance. This paper reports the baseline demographics and characteristics of the population studied as well as the study's progress during the pandemic. Conclusions: This study was designed to generate feasibility insights and validation data to help advance novel digital technologies in clinical drug development. The learnings from this study will help guide future methods for assessing novel digital technologies and inform clinical drug trials in early AD, aiming to enhance clinical end point strategies with digital technologies. International Registered Report Identifier (IRRID): DERR1-10.2196/35442

The large range of potential applications, not only for patients but also for healthy people, that could be achieved by affective BCI (aBCI) makes more latent the necessity of finding a commonly accepted protocol for real-time EEG-based emotion recognition. Based on wavelet package for spectral feature extraction, attending to the nature of the EEG signal, we have specified some of the main parameters needed for the implementation of robust positive and negative emotion classification. 12 seconds has resulted as the most appropriate sliding window size; from that, a set of 20 target frequency-location variables have been proposed as the most relevant features that carry the emotional information. Lastly, QDA and KNN classifiers and population rating criterion for stimuli labeling have been suggested as the most suitable approaches for EEG-base emotion recognition. The proposed model reached a mean accuracy of 98% (s.d. 1.4) and 98.96% (s.d. 1.28) in a subject-dependent approach for QDA and KNN classifier, respectively. This new model represents a step forward towards real-time classification. Although results were not conclusive, new insights regarding subject-independent approximation have been discussed.

In order to develop more precise and functional affective applications, it is necessary to achieve a balance between the psychology and the engineering applied to emotions. Signals from the central and peripheral nervous systems have been used for emotion recognition purposes, however, their operation and the relationship between them remains unknown. In this context, in the present work we have tried to approach the study of the psychobiology of both systems in order to generate a computational model for the recognition of emotions in the dimension of valence. To this end, the electroencephalography (EEG) signal, electrocardiography (ECG) signal and skin temperature of 24 subjects have been studied. Each methodology has been evaluated individually, finding characteristic patterns of positive and negative emotions in each of them. After feature selection of each methodology, the results of the classification showed that, although the classification of emotions is possible at both central and peripheral levels, the multimodal approach did not improve the results obtained through the EEG alone. In addition, differences have been observed between cerebral and physiological responses in the processing emotions by separating the sample by sex; though, the differences between men and women were only notable at the physiological level.